BackRegenxbio Overview

Regenxbio Accounts Payable

Track Regenxbio's accounts payable ($16M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$15.55M
28.21% YoYΔ $-6.11M vs prior year quarter

Peer trimmed avg / median

Loading

Regenxbio Accounts Payable History

Loading

Regenxbio vs. peers: Accounts Payable Comparison

Loading

Regenxbio Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Regenxbio (RGNX) FAQ

As of the most recent data (June 2026), RGNX shows a accounts payable of $16M. That compares with $22M in the prior-year period — down 28.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RGNX's accounts payable is now $16M (was $22M) — a 28.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Regenxbio is outperforming or lagging.

Tracking RGNX's accounts payable over time shows whether Regenxbio is scaling, shrinking, or reshaping that part of the business. The current reading is $16M That compares with $22M in the prior-year period — down 28.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Regenxbio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $16M) with ownership activity and broader fundamentals.

Regenxbio's accounts payable is $16M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.